



Inhaled corticosteroids in COPD: friend or foe?

Alvar Agusti^{1,2,3}, Leonardo M. Fabbri^{4,5}, Dave Singh^{6,7,8}, Jørgen Vestbo⁶, Bartolome Celli⁹, Frits M.E. Franssen^{10,11}, Klaus F. Rabe^{12,13} and Alberto Papi¹⁴

Affiliations: ¹Respiratory Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. ²Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ³CIBER Enfermedades Respiratorias, Spain. ⁴Dept of Medicine, University of Ferrara, Ferrara, Italy. ⁵COPD Center, Sahlgrenska University Hospital, Gothenburg, Sweden. ⁶Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. ⁷Manchester University NHS Foundation Trust, Manchester, UK. ⁸Medicines Evaluation Unit, Manchester, UK. ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ¹⁰Dept of Research and Education, CIRO, Horn, The Netherlands. ¹¹Dept of Respiratory Medicine, Maastricht University Medical Hospital, Maastricht, The Netherlands. ¹²LungenClinic Großhansdorf, member of the German Center for Lung Research (DZL), Großhansdorf, Germany. ¹³Christian Albrechts Universität Kiel, member of the German Center for Lung Research (DZL), Kiel, Germany. ¹⁴Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy.

Correspondence: Alvar Agusti, Respiratory Institute, Hospital Clinic, C/Villarroel 170, 08036 Barcelona, Spain. Email: AAGUSTI@clinic.cat



@ERSpublications

The use of inhaled corticosteroids in patients with COPD must be personalised

<http://ow.ly/ZyFI30lDfUR>

Cite this article as: Agusti A, Fabbri LM, Singh D, *et al*. Inhaled corticosteroids in COPD: friend or foe? *Eur Respir J* 2018; 52: 1801219 [<https://doi.org/10.1183/13993003.01219-2018>].

ABSTRACT The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can result in clear clinical benefits in some patients ("friend") but can be ineffective or even associated with undesired side effects, *e.g.* pneumonia, in others ("foe"). After critically reviewing the evidence for and against ICS treatment in patients with COPD, we propose that: 1) ICS should not be used as a single, stand-alone therapy in COPD; 2) patients most likely to benefit from the addition of ICS to long-acting bronchodilators include those with history of multiple or severe exacerbations despite appropriate maintenance bronchodilator use, particularly if blood eosinophils are >300 cells- μL^{-1} , and those with a history of and/or concomitant asthma; and 3) the risk of pneumonia in COPD patients using ICS is higher in those with older age, lower body mass index (BMI), greater overall fragility, receiving higher ICS doses and those with blood eosinophils <100 cells- μL^{-1} . All these factors must be carefully considered and balanced in any individual COPD patient before adding ICS to her/his maintenance bronchodilator treatment. Further research is needed to clarify some of these issues and firmly establish these recommendations.

Disclaimer: Most authors of this review are (or have been) members of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee; the content of this paper reflects their views, not necessarily those of GOLD.

Received: June 30 2018 | Accepted after revision: Aug 23 2018

Copyright ©ERS 2018

Introduction

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the management of patients with chronic obstructive pulmonary disease (COPD) is much debated. Here, we review the evidence available for (“friend”) and against (“foe”) ICS use in COPD and propose that ICS, added to one or two long-acting bronchodilators (never as stand-alone medication), can benefit some (but not all) COPD patients. The challenge is to identify those patients with the highest benefit/risk ratio in clinical practice. Of note, this is not a systematic literature review, it is a narrative review based on the clinical experience and judgement of authors, supported by selected references.

Available evidence for and against the use of ICS in COPD

Many studies have explored the efficacy and safety of ICS in patients with COPD. Results depend on the characteristics of the population studied, the comparator treatment and the selected clinical outcome(s).

Exacerbations of COPD

Early randomised controlled trials (RCTs) did not show an effect of ICS monotherapy on exacerbations of COPD (ECOPD) rate/severity; although, since they investigated the potential effects of ICS on lung function decline, they were not enriched with patients at increased risk of ECOPD [1, 2].

Later RCTs of ICS/long-acting β_2 -agonist (LABA) combinations generally recruited patients with ≥ 1 ECOPD in the previous year, and showed that ICS/LABA combinations reduce ECOPD rates by approximately 25–35% compared with LABA monotherapy (figure 1) [3–14]. Likewise, despite not specifically focusing on patients at increased ECOPD risk, TORCH and SUMMIT were large enough to demonstrate ICS efficacy on ECOPD [15, 16]. More recently, two RCTs (IMPACT and TRIBUTE) compared triple therapy *versus* LABA/long-acting muscarinic antagonist (LAMA) combinations in patients at high ECOPD risk, and also showed a 15–25% reduction in ECOPD rates (figure 1) [17, 18].

Another way to assess the efficacy of a given therapeutic option is the calculation of the number needed to treat (NNT). Person-based NNTs are often thought to be superior to event-based NNTs, as the latter is




FIGURE 1 Percentage reduction in the annual rate of moderate/severe exacerbations of chronic obstructive pulmonary disease (ECOPD) for the comparison inhaled corticosteroids (ICS)/long-acting β_2 -agonist (LABA) *versus* LABA (left) and for ICS/LABA/long-acting muscarinic antagonist (LAMA) *versus* LABA/LAMA (right) in published studies [3–5, 7–15, 17, 18]. *: $p < 0.05$. #: significance could not be inferred because of hierarchy of statistical testing. Reference [6] is not included as rate ratios are not reported.

influenced by the reduction in ECOPD rate in patients with frequent exacerbations, rather than by the proportion of them with no ECOPD events. This, however, makes person-based NNTs less applicable in the real world where patients often have higher ECOPD rates than in tightly controlled RCTs [19]. Although neither IMPACT nor TRIBUTE includes NNTs in their published results [17, 18], values can be approximated from their respective publications. In IMPACT [17], the event-based NNT to prevent one ECOPD for triple therapy *versus* umeclidinium/vilanterol (UMEC/VI) with a 25% reduction in ECOPD lies between 3 and 4, whereas for triple therapy *versus* fluticasone furoate (FF)/VI, with a 15% reduction in ECOPD, it lies between 6 and 7. The corresponding person-based NNT is 25 for triple therapy *versus* UMEC/VI whereas, according to the Kaplan–Maier plot in the publication [17], there was no reduction in the number of patients with ECOPD for triple therapy *versus* FF/VI. In TRIBUTE [17, 18], with an overall low ECOPD rate (0.50 and 0.59 events per patient per year), a 15% reduction with beclomethasone/formoterol/glycopyrronium (BDP/FF/G) *versus* indacaterol/glycopyrronium (IND/GLY) results in an event-based NNT between 11 and 12, and a person-based NNT of approximately 50. These figures compare quite favourably with other chronic treatments: for example, 5-year NNTs of 53 for statins to prevent one coronary heart disease event [20], and 24 for anti-hypertensives to prevent one cardiovascular disease event [21]. However, it is still important to consider that the calculation of event-based NNTs depends directly on the underlying rate of the event of interest (ECOPD in this case), so NNT is lower in frequent exacerbators and higher in those patients with only occasional ECOPD events.

The potential effect of triple therapy compared with LABA/LAMA or ICS/LABA on the rate of *severe* ECOPD (*i.e.* those leading to hospitalisation) is also clinically relevant. Neither IMPACT nor TRIBUTE were powered on this outcome [17, 18]. However, in IMPACT, the annual rates of *severe* ECOPD during treatment were 0.13 with triple therapy, 0.15 with FF/VI (13% difference; $p=0.06$), and 0.19 with umeclidinium (UMEC)/VI (34% difference; $p<0.001$) [17]. In TRIBUTE, the annual *severe* ECOPD rate was 0.07 in the beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) arm *versus* 0.09 in the indacaterol/glycopyrronium (IND/GLY) arm (21% difference; $p=0.189$) [18]. Whether the reduction of *severe* ECOPD with triple therapy *versus* LABA/LAMA, which was statistically significant in IMPACT, is also clinically relevant warrants confirmation in studies focusing on patients with recurring hospitalisations, since, both in IMPACT and TRIBUTE, the incidence of those events was quite low [17, 18, 22]. Finally, the use of a single inhaler for any ICS-containing combination therapy (ICS/LABA or ICS/LABA/LAMA) might improve a patient's adherence but, since available studies were not powered for this, it remains to be formally ascertained.

In summary, there is strong evidence that, in patients with previous ECOPD despite long-acting bronchodilator treatment, the addition of ICS reduces the risk of future ECOPD [23, 24].

Survival

Currently available information on the effects of ICS on survival in patients with COPD comes from three different sources: RCTs with mortality as the primary outcome, RCTs where mortality is a secondary or safety measure (not the primary outcome), and observational and registry studies.

RCTs with mortality as the primary outcome

Only two RCTs can be included in this category. 1) TORCH showed a 17.5% reduction in the risk of death in the ICS/LABA group *versus* placebo, but this difference just failed to reach statistical significance (HR 0.825 (95% CI 0.681–1.002); $p=0.052$) [15]. This result has been much debated, since a high placebo drop-out rate and statistical adjustment for an interim analysis might have impacted the ability to achieve a p -value <0.05 [25]; with the given absolute risk reduction of 2.6%, NNT would be 38. In a pre-specified secondary analysis, both the Cox model and Log-rank test suggested a mortality benefit to the ICS/LABA arm *versus* placebo [15]. 2) SUMMIT, which selectively recruited COPD patients with moderate airflow limitation and heightened cardiovascular risk, did not show a mortality risk reduction for ICS/LABA *versus* placebo (HR 0.88 (0.74–1.04); $p=0.137$) [16].

RCTs with mortality as a secondary outcome

Three analyses can be included in this category. 1) In INSPIRE, ICS/LABA was associated with reduced mortality *versus* LAMA therapy (3% *versus* 6%; $p=0.032$) [26]. 2) In IMPACT, ICS-containing treatments were associated with lower mortality *versus* LABA/LAMA (triple *versus* LABA/LAMA: HR 0.58 (0.38–0.88); $p=0.01$; ICS/LABA *versus* LABA/LAMA: 0.61 (0.40–0.93); $p=0.02$) [17, 27]. Of note, however, patients with a previous history of asthma could be enrolled in IMPACT and this may have influenced results. Using the reported mortality rates, the NNT in IMPACT would be 256. 3) A *post hoc* analysis of pooled data from TRILOGY, TRINITY and TRIBUTE showed a non-significant reduction in the hazard ratio of fatal events for ICS-containing *versus* ICS-free treatments (triple *versus* LABA or LABA/LAMA:

HR 0.72 (0.49–1.06); $p=0.096$) [28]. The estimated NNT in this pooled analysis, with the calculations based on the proportion of patients and not taking time to event into account, would be 141.

Observational and registry studies on the effects of ICS on mortality

The results of these studies suggest reduced mortality in patients receiving ICS-containing therapy, mostly after discharge from hospitalisation due to ECOPD [29–33]. Although they are not RCTs, their results can be clinically relevant since patients included in these studies are more likely to be elderly, multi-morbid, frail, and at high risk of re-hospitalisation and death [34, 35]. However, registry studies can have significant biases [36], including immortal time bias [30, 31], immeasurable time bias [32, 37] and “asthma” bias [38], although it is important to note that none of these potential biases has been proven to be the real explanation for the observed benefits of ICS in this population, so the latter may still represent real clinical differences. Importantly, no “real world” study on mortality in patients with COPD has optimised the treatment of other concomitant disorders that are almost invariably present in these patients, including heart failure, coronary artery disease, stroke, diabetes and hypertension, whose appropriate treatment reduces mortality [35, 39, 40].

In summary, currently available evidence from RCTs fails to show that the addition of ICS to long-acting bronchodilator therapy improves survival significantly in patients with COPD. However, secondary or safety analyses of RCTs and observational data suggest that certain subtypes of COPD patients may benefit, particularly those with severe airflow limitation and/or frequent exacerbations. Further prospective research is needed to confirm or refute this clinically relevant possibility.

Health-related quality of life

Many previous studies [13, 17, 18, 41] have shown that ICS therapy improves health-related quality of life (HRQoL), as measured by the St George’s Respiratory Questionnaire (SGRQ) total score, but the effect size (1.5–2.5 units) is lower than the minimal clinically important difference (4 units) [42]. However, there is controversy regarding the use of this four-unit threshold to compare active treatments [43–45]. In the case of ICS, there is significant inter-individual response variability [18], which is likely to influence the proportion of SGRQ “responders” versus “non-responders” [46]. With this caveat in mind, in IMPACT, 42% of participants responded (*i.e.* improved their SGRQ total score from baseline by more than 4 units) to triple therapy, whereas 34% responded to ICS/LABA or LABA/LAMA [17]. This means that, for every 100 patients treated with triple instead of one of the two dual combinations, an extra eight patients would have a clinically relevant improvement in SGRQ, which results in an NNT of approximately 13. Whether this benefit is driven by fewer ECOPDs is unclear but possible, since ECOPD events worsen SGRQ total scores, and in some individuals there is a long recovery time (many months) to return to the baseline value [47]. An alternative explanation is that the ICS anti-inflammatory effect in the stable state improves lung function and thereby contributes to a symptomatic improvement.

In summary, the effects of ICS on HRQoL vary significantly between patients; identifying and validating markers of HRQoL response in COPD remains a challenge.

Lung function

In studies lasting 6–12 months, the addition of ICS to a bronchodilator improved forced expiratory volume in the first second (FEV₁) in the range of 30–90 mL [3, 4, 6, 8, 9, 11–14]. Yet, longer RCTs (3-year) with FEV₁ decline as the primary outcome failed to show a significant effect from ICS monotherapy [1]. This may not be surprising, given that the rate of FEV₁ decline varies greatly among patients with treated COPD [48, 49], and that there are different FEV₁ trajectories leading to COPD [50]. However: 1) a *post hoc* analysis of TORCH showed a reduction in FEV₁ decline in patients treated with ICS versus placebo (difference 13.0 mL·year⁻¹; $p=0.003$) but not versus LABA (difference 3.3 mL·year⁻¹; $p=0.441$) [51]; 2) in a pre-specified analysis of FEV₁ decline as a secondary outcome in SUMMIT, treatment with ICS, either alone or in combination with a LABA, was associated with a 8 mL·year⁻¹ reduction in FEV₁ decline [16, 52], similar to that seen in a previous meta-analysis [53]; 3) a factorial analysis of SUMMIT suggested that the ICS component drives the improvement in FEV₁ decline, whereas the effect on ECOPD reduction appears additive (ICS and LABA) [54]; 4) a *post hoc* analysis of FEV₁ decline in ISOLDE reported a more pronounced effect of ICS in patients with higher eosinophils [55]; 5) in the GLUCOLD study, for which bronchial biopsies were obtained at baseline and during therapy with ICS/LABA or placebo, gene expression differed between those who had a significant increase in FEV₁ over the duration of the study versus those whose lung function declined over the same period [56]; and, finally 6) meta-analyses of 3-year trials provide conflicting results [53, 57, 58].

In summary, the effects of ICS on lung function vary between COPD patients and are numerically small.

Infections

ICS can impair monocyte chemotaxis, bactericidal activity, interleukin (IL)-1 and tumour necrosis factor α production, and T-cell activation [59, 60], thereby increasing the risk of respiratory infections such as pneumonia [15], oropharyngeal candidiasis [61–63], mycobacterial [64, 65] and upper respiratory tract (URTIs).

Pneumonia

The risk of pneumonia in both smokers and patients with COPD is increased regardless of ICS use [66, 67] but ICS treatment further increases this risk [7, 13, 15, 26, 68–73], as acknowledged in 2016 by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency [74]. This is the case regardless of whether pneumonia events are reported based on a clinical diagnosis or chest radiograph [12, 18, 68]. More recently (in 2018), the incidence of pneumonia associated with single-inhaler triple therapies has been compared with that associated to treatment with ICS/LABA, LABA/LAMA or LAMA [17, 18, 75, 76]. In IMPACT, the incidence of pneumonia was higher in patients treated with FF/VI/UMEC than UMEC/VI (8% versus 5%; figure 2a) [17] whereas, in TRIBUTE, BDP/FF/G was not associated with a higher incidence of pneumonia when compared with IND/GLY (4% with each; figure 2b) [18, 77]. Likewise, in SUMMIT, the risk of pneumonia was not increased by ICS therapy [16, 78].

Differences in pneumonia incidence/risk may be due to: 1) differences in study design or adverse event reporting [79, 80]; 2) characteristics of the population studied, such as older age (≥ 55 years versus < 55 years, HR 1.62 (1.21–2.15) [81]; ≥ 65 years, ICS/LABA versus LABA HR 3.3 (1.2–8.7) [79]), lower BMI (< 25 kg·m⁻², ICS/LABA versus LABA HR 3.4 (1.4–8.4) [79, 81]), more severe airflow limitation (FEV₁ 30–50% predicted, ICS/LABA versus LABA HR 2.9 (1.1–8.0) [79, 81]), frequent ECOPD (≥ 1 versus 0 HR 1.25 (1.08–1.45) [81]) and low blood eosinophil counts [82–84], although this has not been observed in all studies [85]; 3) higher ICS doses, although available evidence on this topic is not conclusive since head-to-head comparisons of different ICS doses in RCT are rare and available data do not show a dose-related increase in the pneumonia risk for FF/VI or for fluticasone propionate/salmeterol (FP/SAL) [79, 86]. Furthermore, indirect comparisons between studies of high versus medium/low ICS doses are difficult due to differences in design, specific drugs tested, previous treatments and/or severity of airflow limitation. Yet, the incidence of pneumonia increases even when medium doses of ICS (250 μ g) are used (7% FP/SAL versus 2% SAL [10]; 7% FP/SAL versus 4% SAL [8]) and, importantly, patients receiving ≥ 1000 μ g·day⁻¹ of FP equivalent were at the greatest risk (RR 2.25 (2.07–2.44)) [87]; and/or 4) different ICS molecules [79, 80]. The event-based number needed to harm (NNH) was 33 for FP in TORCH [15] and 34 for FF in IMPACT [17]. For budesonide, the risk of pneumonia seems to be lower, although the budesonide studies were shorter, and so are less precise [79, 80]. In fact, a Cochrane review concluded that both budesonide and fluticasone are associated with increased risk of serious adverse pneumonia events




FIGURE 2 Effect of different pharmacological combinations on exacerbations of chronic obstructive pulmonary disease (ECOPD) and pneumonia both in the a) IMPACT [17] and b) TRIBUTE [77] studies (reproduced with permission from the authors). Note that in panel a, all bars indicate the incidence of events (as events per patient per year) but ECOPD results are shown as RR values, whereas those of pneumonia are shown as HR values for time to first event. In panel b, all lines indicate incidence of events. FF: fluticasone furoate; VI: vilanterol; UMEC: umeclidinium; BDP/FF/G: beclometasone dipropionate, formoterol fumarate and glycopyrronium; IND/GLY: indacaterol and glycopyrronium.

requiring hospitalisation [73]. Event-based NNH estimates for BDP are approximately 50 for BDP/FF *versus* FF in FORWARD and 120 for BDP/FF/G *versus* tiotropium in TRINITY, but cannot be calculated for TRIBUTE as there was no difference between triple and LABA/LAMA [13, 18, 75].

On a final note, it is unclear whether the occurrence of ICS-associated pneumonia increases mortality in patients with COPD [15, 87–89]. Retrospective/cohort studies that assessed mortality in subjects with COPD hospitalised with pneumonia in relation to previous ICS treatment reported conflicting results [87, 90, 91]. A Canadian study reported that the risk of pneumonia hospitalisation followed by death was increased in patients receiving ICS *versus* control, with the rate ratio of hospitalisation being highest in those receiving high-dose ICS (≥ 1000 μg FP equivalent). However, 30-day all-cause mortality was not increased [87]. In contrast, two large retrospective studies reported that prior receipt of ICS was associated with decreased mortality at 30 days and 90 days (OR 0.80 and 0.78, respectively) in ICS treated patients hospitalised for pneumonia [90, 91]. However, a RCT assessing pneumonia-related deaths was not conclusive likely due to the low frequency of events reported [73].

In summary, the use of ICS in COPD increases the risk of pneumonia, particularly in patients with older age, lower BMI, severe airflow limitation and low blood eosinophil counts [81, 82].

Mycobacteria

Observational studies suggest that patients with COPD receiving treatment with ICS have an increased risk of active tuberculosis in high prevalence areas, such as South Korea (RR 1.84 (1.56–2.17)) [92] and Taiwan (HR 4.74 (1.01–22.37) for high ICS doses) [93]. Yet, a similar trend has been reported in settings with low tuberculosis prevalence, such as Canada [94]. Further, these observations have been supported by meta-analyses of data from RCTs [65]. The risk of tuberculosis seems particularly pronounced in older males with a history of previous hospitalisations for COPD and in those with more severe lung function impairment [95]. The ICS dose associated with increased tuberculosis risk was >500 $\mu\text{g}\cdot\text{day}^{-1}$ FP or equivalent in the study from Taiwan [93].

In case-control studies, COPD has been identified as a risk factor for infection with non-tuberculous mycobacteria (NTM), with a ICS dose-related increased risk [96]. A Canadian database analysis confirmed the increased risk of NTM pulmonary disease among patients with COPD treated with ICS-containing medications (OR 2.09 (1.80–2.43)) with a dose-response relationship for yearly cumulative dose of FP, but not budesonide [97].

Viruses

Long-term ICS use increases URTI risk, including rhinovirus, respiratory syncytial virus and coronavirus [98]. The association is particularly significant in patients receiving high ICS doses, and appears more consistent with FP [98]. A meta-analysis of 26 trials showed that the risk of influenza was not significantly increased in patients with COPD who were receiving ICS; however, there was a statistically significant difference when only the FP studies were considered [65].

Candidiasis

An observational, matched cohort study showed that patients receiving ICS/LABA had significantly greater odds of experiencing oral thrush than those prescribed LABA alone, with a dose-dependent effect for FP/SAL [63]. RCTs have also reported an increased risk of oropharyngeal candidiasis with ICS (OR 2.65 (2.03–3.46)) [99].

ICS withdrawal

Several studies have investigated the impact of ICS withdrawal in patients with COPD with contrasting results. Potential confounders include study design (observational *versus* RCT), severity of airflow limitation of the patients studied, outcomes assessed, duration of follow up, background inhaled treatment (placebo *versus* long-acting bronchodilator(s)), definition and previous history of ECOPD, and/or duration of run-in and/or wash-out periods [100].

The ISOLDE trial was the first to report an increased rate of ECOPD following acute ICS withdrawal (during the run-in period) in patients previously treated with ICS, compared with patients never treated with ICS [101]. Similarly, O'BRIEN *et al.* [102] reported a statistically non-significant increase in ECOPD rate after ICS withdrawal in a six-week RCT which was accompanied by a 100-mL FEV₁ decrease. The COPE study showed that the hazard ratio of a first ECOPD episode in patients who discontinued ICS was 1.5 compared with those continuing ICS [103]. The COSMIC study, which included patients with moderate-to-severe COPD with at least two ECOPD in the previous year, showed that ICS withdrawal resulted in a prompt and persistent decrease in FEV₁ of about 4% and an increase in respiratory

symptoms, although no significant differences in the rate of moderate or severe ECOPD between groups was observed during the subsequent year [104]. Another RCT in patients in primary care in the UK reported an almost 50% increased risk of ECOPD over 1 year following ICS withdrawal [105]. A systematic review of these three early RCTs [103–105] concluded that, although outcomes were generally worse for patients in whom ICS was withdrawn, differences were mostly small and not statistically significant [106].

The WISDOM study was the first RCT specifically designed to investigate the effects of a stepped ICS withdrawal on the frequency of ECOPD and rate of FEV₁ decline in a large population of severe COPD patients with ≥ 1 ECOPD in the previous 12 months, with all patients receiving triple therapy during the 6-week run-in period. ICS withdrawal did not increase the risk of moderate or severe ECOPD but was again associated with a reduction in FEV₁ [107, 108]. The interpretation of these data may be clouded by the fact that only 39% of patients were on triple therapy before inclusion, which could favour a lack of effect of ICS withdrawal.

The “real life” DACCORD study reported no increased risk of ECOPD in patients with COPD managed in the primary and secondary care during 2 years after ICS withdrawal [109]. The GLUCOLD study group reported accelerated lung function decline in patients with moderate COPD after ICS discontinuation over a 5-year follow up [110]. Of note, in this biopsy study, ICS withdrawal resulted in increased airway inflammation [111]. Finally, the INSTEAD study suggested that in patients with moderate COPD and no history of ECOPD, ICS could be discontinued safely; however, it should be noted that follow-up in this study lasted only for 26 weeks [112]. This was recently confirmed in the SUNSET study, in which direct de-escalation from long-term triple therapy to LABA/LAMA in patients without frequent ECOPD episodes led to a small decrease in lung function, with no difference in ECOPD [113, 114].

In summary, ICS withdrawal results in a slight but consistent deterioration of lung function (FEV₁) and airway inflammation, whereas the effects upon the rate of ECOPD varies across studies, likely in relation to the type of patients studied (high *versus* low blood eosinophils), concurrent bronchodilation maintenance therapy and previous history of ECOPD.

Personalised ICS treatment in COPD

From the evidence reviewed above, it seems clear that some COPD patients may benefit from the addition of ICS to their long-acting bronchodilator maintenance treatment whereas others don't. Thus, the risk/benefit ratio of adding (or withdrawing) ICS has to be carefully considered in each individual patient. The challenge is, therefore, how to identify what markers can help to identify in the clinic those COPD patients who can benefit most from ICS use at the lowest risk possible of undesired side effects (table 1).

Clinical markers of potential ICS benefit

To ascertain which patients with COPD can benefit more from the addition of ICS to their maintenance long-acting bronchodilator treatment it is important to define what is the specific outcome that we want to target. 1) Death: currently available evidence from RCTs does not support that the addition of ICS improves mortality in COPD patients. Yet, secondary analyses and observational data suggest a potential beneficial effect in certain subgroups, particularly in those with severe disease, frequent exacerbations [15–17], and/or history of (or concomitant) asthma [115], albeit this has never been confirmed in a formal RCT [116]. While waiting for further prospective research to confirm or refute this possibility, if the therapeutic target is survival, it seems advisable to use clinical judgment to balance the benefit/risk ratio of adding/avoiding ICS in individual patients. 2) Rate of ECOPD: available evidence here is clear, ICS are indeed effective at all stages of airflow limitation [17, 18, 70, 117]. 3) HRQoL: the response to the addition

TABLE 1 Factors to consider when initiating inhaled corticosteroids (ICS) treatment (in combination with one or two long-acting bronchodilators) in chronic obstructive pulmonary disease (COPD) patients (the scenario is different when considering ICS withdrawal; see text)

Strong support	Consider use	Avoid use
History of hospitalisation(s) for exacerbations of COPD [#] ≥ 2 moderate exacerbations of COPD per year [#] Blood eosinophils >300 cells- μL^{-1} History of, or concomitant, asthma	1 moderate exacerbation of COPD per year [#] Blood eosinophils 100–300 cells- μL^{-1}	Repeated pneumonia events Blood eosinophils <100 cells- μL^{-1} History of mycobacterial infection

[#]: despite appropriate long-acting bronchodilator maintenance therapy.

of ICS varies significantly between patients [118]. 4) Lung function decline: older patients, current smokers, patients with more severe airflow limitation and lower BMI will benefit less [51].

Clinical markers of potential ICS risk

Factors associated with an increased risk of pneumonia in patients with COPD treated with ICS include older age (>55 years), BMI <25 kg·m⁻², greater severity of airflow limitation (FEV₁ 30–50% predicted), prior ECOPD history and low blood eosinophil counts [72, 81]. Thus, in clinical practice, it seems advisable to discontinue ICS if repeated episodes of pneumonia are documented (albeit there is no proof of increased risk of death from these pneumonias [79, 119]). Analyses of large databases also suggest that ICS use in COPD is associated with increased risk of diabetes (RR 1.34 (95% CI 1.29–1.39)) [120, 121], particularly with the highest ICS doses (≥1000 µg per day fluticasone equivalent; RR 1.64 (1.52–1.76)) [120, 121], cataract (current ICS users had twice the risk of incident posterior subcapsular cataract; OR 2.5 (1.3–4.7)) or incident nuclear cataract (OR 2.0 (1.2–3.4)) [122] and osteoporosis/fractures (OR 1.21 (1.12–1.32) ICS current or ever users *versus* non-users) [123, 124], so these potential undesired side effects need to be monitored in clinical practice. Finally, it is important to consider that the dose or specific type of ICS molecule used may also influence the risk for undesired outcomes [119, 125].

Blood eosinophils to guide ICS use in COPD

There is an emerging pattern that suggests that blood eosinophil levels can be a potentially useful biomarker to identify those patients with COPD in whom the addition of ICS to their long-acting maintenance therapy is more likely to reduce the risk of future exacerbations. Although no RCT has yet explored directly the response to ICS in this type of patients according to their blood eosinophil levels, the following observations do support this pattern. 1) *Post hoc* analyses of RCTs comparing ICS/LABA *versus* LABA showed that, in patients treated with LABA only, the ECOPD rate was higher in those patients with higher blood eosinophil counts, and that ICS prevent future ECOPD most effectively in such patients (figure 3a) [17, 126]; 2) two recent RCTs of triple therapy *versus* LABA/LAMA (IMPACT and TRIBUTE) pre-specified the analysis of blood eosinophils to determine the level of response to the investigated therapies and confirmed greater ICS effects in patients with ≥150–200 eosinophils·µL⁻¹ [17, 18]; 3) the FLAME study showed fewer moderate-to-severe exacerbations with LABA/LAMA treatment compared to ICS/LABA (17% treatment difference) [68], with a *post hoc* analysis showing that the lowest response to ICS/LABA was in patients with <150 eosinophils·µL⁻¹ [127]; 4) ICS withdrawal in WISDOM caused increased ECOPD in patients with ≥300 eosinophils·µL⁻¹ [128, 129]; and 5) using continuous negative binomial regression modelling, a threshold of ≥100 eosinophils·µL⁻¹ appeared to predict a positive ICS response, with greater effect sizes at higher eosinophil counts (figure 3b) [130].




FIGURE 3 Influence on the relative effect of inhaled corticosteroids (ICS)-containing *versus* non-ICS-containing therapies on annualised exacerbations of chronic obstructive pulmonary disease [ECOPD] rates at different eosinophil levels: a) percentage of ECOPD rate reduction in FORWARD [126], IMPACT [17] and TRIBUTE [18] by blood eosinophil levels; b) pooled analysis of three studies comparing ICS/long-acting beta₂-agonist (LABA) *versus* LABA showing ECOPD incidence by eosinophil level [reproduced from [130] with permission from the publisher].

Alternatively, there are arguments against the use of blood eosinophils as a clinically useful biomarker of ICS response in COPD. 1) The relationship between blood and sputum eosinophils is poor or absent [131–133]. However, sputum eosinophils are prone to variability, and bronchoscopic sampling reported more eosinophilic airway inflammation in those patients with COPD who had higher blood eosinophil counts [134]. 2) Blood eosinophils show variability, particularly when using higher (e.g. 300 eosinophils- μL^{-1}) than lower (e.g. 100 eosinophils- μL^{-1}) thresholds [83, 135, 136]. 3) Some observational cohort studies have found no association between systemic eosinophil levels and outcomes, including exacerbations, hospitalisations and mortality, while others did [137, 138]. 4) Finally, recent studies have shown that the IL-5 antibody mepolizumab nearly eliminate circulating eosinophils yet influence ECOPD modestly [139]. However, this does not exclude the possibility that blood eosinophils may be a biomarker of other biological processes (not necessarily an effector molecule) that favour ICS benefit (e.g. less bacterial colonisation or different T-helper 2 biology). Further studies are needed to elucidate these possibilities.

Considering all these pro–con arguments, we propose the following practical strategy for the addition/avoidance of ICS in individual patients with COPD who still suffer frequent ECOPD episodes despite appropriate bronchodilator therapy: 1) given that <100 eosinophils- μL^{-1} seems a useful and reproducible threshold to predict a poor response to ICS in terms of ECOPD prevention, we would suggest limiting their use in these patients, unless the individual patient has a history of asthma; 2) alternatively, because >300 eosinophils- μL^{-1} seems to predict a beneficial ICS response in terms ECOPD risk reduction [130, 137], we would support the addition of ICS to long-acting bronchodilator therapy in those patients who still experience ECOPD despite appropriate bronchodilator treatment; and, finally, 3) there is an intermediate group of patients, with 100–300 eosinophils- μL^{-1} , for whom current evidence is insufficient to make a firm recommendation. In this group, a careful consideration of the potential benefits and risks discussed above should be individually considered. Needless to say that this strategy must be validated in prospective studies. The role of other biomarkers to predict ICS response in COPD remains unknown and requires further research.

Conclusions

Since ICS in COPD can be both “friend” and “foe”, their addition to long-acting bronchodilator maintenance therapy in these patients must be personalised. To this end, a number of clinical and biological markers related to their benefits and risks (table 1) can help clinicians to decide on their use in an individual patient.

Conflict of interest: A. Agusti reports receiving grants from GSK; lectures fees from Novartis and Chiesi; grants, and lecture and advisory board fees from AstraZeneca; and lecture and advisory board fees from Boehringer Ingelheim, all outside the submitted work. L.M. Fabbri reports being paid for lectures and membership of advisory boards, and receiving travel expense reimbursement and grants for research from Boehringer Ingelheim, Chiesi, GSK, Merck Sharp & Dhome, Takeda, AstraZeneca, Novartis, Menarini, Laboratori Guidotti and Almirall; being paid for lectures and membership of advisory boards, and receiving travel expense reimbursement from Pearl Therapeutics, Mundipharma, Boston Scientific and Zambon; being paid for lectures by Kyorin and Bayer; and has received grants for research from Pfizer, Dompe, Malesci, Biofutura Italia and Vree Health Italia. D. Singh reports grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Therevance, and Verona; and personal fees from Genentech and Skyepharma, all outside the submitted work. J. Vestbo reports receiving personal fees for consultancy on COPD phase 2 and 3 programmes, and payment for lectures including service in speaker bureau, from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, outside the submitted work. B. Celli reports personal fees and funding for a research site from AstraZeneca, and consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, Chiesi and Menarini, all outside the submitted work. F.M.E. Franssen reports receiving personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Teva; and grants and personal fees from Novartis, all outside the submitted work. K.F. Rabe reports receiving consultancy and speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Teva, Intermune, Chiesi Pharmaceuticals and Berlin Chemie; and grants from Ministry of Education and Science, Germany, outside the submitted work. A. Papi reports receiving fees for board membership, consultancy, payment for lectures, grants for research, travel expense reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma, and TEVA; payment for lectures and travel expense reimbursement from Menarini, Novartis and Zambon; and grants for research from Sanofi, all outside the submitted work.

Support statement: Editorial support was provided by David Young of Young Medical Communications and Consulting Ltd, which was funded by the Consorzio Futuro in Ricerca of Ferrara, Italy. Jørgen Vestbo and Dave Singh are supported by the NIHR Manchester Biomedical Research Centre.

References

- 1 Pauwels RA, Löfdahl CG, Laitinen LA, *et al.* Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med* 1999; 340: 1948–1953.
- 2 Vestbo J, Sørensen T, Lange P, *et al.* Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 1999; 353: 1819–1823.

- 3 Calverley PM, Boonsawat W, Cseke Z, *et al.* Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. *Eur Respir J* 2003; 22: 912–919.
- 4 Szafranski W, Cukier A, Ramirez A, *et al.* Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21: 74–81.
- 5 Papi A, Döck D, Tzimas W, *et al.* Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1961–1971.
- 6 Calverley PMA, Kuna P, Monsó E, *et al.* Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. *Respir Med* 2010; 104: 1858–1868.
- 7 Kardos P, Wencker M, Glaab T, *et al.* Impact of salmeterol/fluticasone propionate *versus* salmeterol on exacerbations in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007; 175: 144–149.
- 8 Ferguson GT, Anzueto A, Fei R, *et al.* Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. *Respir Med* 2008; 102: 1099–1108.
- 9 Rennard SI, Tashkin DP, McElhattan J, *et al.* Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. *Drugs* 2009; 69: 549–565.
- 10 Anzueto A, Ferguson GT, Feldman G, *et al.* Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. *COPD* 2009; 6: 320–329.
- 11 Sharafkhaneh A, Southard JG, Goldman M, *et al.* Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. *Respir Med* 2012; 106: 257–268.
- 12 Dransfield MT, Bourbeau J, Jones PW, *et al.* Once-daily inhaled fluticasone furoate and vilanterol *versus* vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. *Lancet Respir Med* 2013; 1: 210–223.
- 13 Wedzicha JA, Singh D, Vestbo J, *et al.* Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. *Respir Med* 2014; 108: 1153–1162.
- 14 Calverley P, Pauwels R, Vestbo J, *et al.* Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2003; 361: 449–456.
- 15 Calverley PMA, Anderson JA, Celli B, *et al.* Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356: 775–789.
- 16 Vestbo J, Anderson JA, Brook RD, *et al.* Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet* 2016; 387: 1817–1826.
- 17 Lipson DA, Barnhart F, Brealey N, *et al.* Once-daily single-inhaler triple *versus* dual therapy in patients with COPD. *N Engl J Med* 2018; 378: 1671–1680.
- 18 Papi A, Vestbo J, Fabbri L, *et al.* Extrafine inhaled triple therapy *versus* dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet* 2018; 391: 1076–1084.
- 19 Woodcock A, Boucot I, Leather DA, *et al.* Effectiveness *versus* efficacy trials in COPD: how study design influences outcomes and applicability. *Eur Respir J* 2018; 51: 1701531.
- 20 Rossignol M, Labrecque M, Cauchon M, *et al.* Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality. *Fam Pract* 2018; 35: 376–382.
- 21 Basu S, Sussman JB, Rigdon J, *et al.* Benefit and harm of intensive blood pressure treatment: derivation and validation of risk models using data from the SPRINT and ACCORD trials. *PLOS Med* 2017; 14: e1002410.
- 22 Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. *N Engl J Med* 2018; 378: 1723–1724.
- 23 Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. *Lancet* 2017; 389: 1864–1865.
- 24 Agusti A. Filling the gaps in COPD: the TRIBUTE study. *Lancet* 2018; 391: 1004–1006.
- 25 Rabe KF. Treating COPD — the TORCH trial, p values, and the dodo. *N Engl J Med* 2007; 356: 851–854.
- 26 Wedzicha JA, Calverley PMA, Seemungal TA, *et al.* The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med* 2008; 177: 19–26.
- 27 Lipson DA, Barnhart F, Brealey N, *et al.* Reduction in all-cause mortality with single inhaler triple therapy (FF/UMEC/VI) *versus* dual therapy (FF/VI and UMEC/VI) in symptomatic patients with COPD: prespecified analysis of the Phase III IMPACT Trial. *Am J Respir Crit Care Med* 2018; 197: A1015.
- 28 Vestbo J, Fabbri LM, Papi A, *et al.* Inhaled corticosteroid containing combinations and mortality in COPD. *Eur Respir J* 2018; 52: 1801230.
- 29 Zervas E, Samitas K, Gaga M, *et al.* Inhaled corticosteroids in COPD: pros and cons. *Curr Drug Targets* 2013; 14: 192–224.
- 30 Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; 164: 580–584.
- 31 Soriano JB, Vestbo J, Pride NB, *et al.* Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. *Eur Respir J* 2002; 20: 819–825.
- 32 Kiri VA, Pride NB, Soriano JB, *et al.* Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. *Am J Respir Crit Care Med* 2005; 172: 460–464.
- 33 Di Martino M, Agabiti N, Cascini S, *et al.* The effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in Italy. *COPD* 2016; 13: 293–302.
- 34 Müllerova H, Maselli DJ, Locantore N, *et al.* Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. *Chest* 2015; 147: 999–1007.
- 35 Vanfleteren LEGW, Ullman A, Fabbri LM. Time for a longer and better life for patients with COPD. *Eur Respir J* 2018; 51: 1702569.
- 36 Suissa S, Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. *Chest* 2018; 154: 257–265.
- 37 Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. *Am J Epidemiol* 2008; 168: 329–335.

- 38 Gershon AS, Campitelli MA, Croxford R, *et al.* Combination long-acting β -agonists and inhaled corticosteroids compared with long-acting β -agonists alone in older adults with chronic obstructive pulmonary disease. *JAMA* 2014; 312: 1114–1121.
- 39 Rose L, Istanboulian L, Carriere L, *et al.* Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC COPD+): a randomised controlled trial. *Eur Respir J* 2018; 51: 1701567.
- 40 Kessler R, Casan-Clara P, Koehler D, *et al.* COMET: a multicomponent home-based disease-management programme *versus* routine care in severe COPD. *Eur Respir J* 2018; 51: 1701612.
- 41 Horita N, Goto A, Shibata Y, *et al.* Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) *versus* LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). *Cochrane Database Syst Rev* 2017: CD012066.
- 42 Jones PW, Beeh KM, Chapman KR, *et al.* Minimal clinically important differences in pharmacological trials. *Am J Respir Crit Care Med* 2014; 189: 250–255.
- 43 Wedzicha JA, Decramer M, Ficker JH, *et al.* Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med* 2013; 1: 199–209.
- 44 Maleki-Yazdi MR, Kaelin T, Richard N, *et al.* Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. *Respir Med* 2014; 108: 1752–1760.
- 45 Singh D, Jones PW, Bateman ED, *et al.* Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. *BMC Pulm Med* 2014; 14: 178.
- 46 Jones PW, Gelhorn H, Wilson H, *et al.* Responder analyses for treatment effects in COPD using the St George's Respiratory Questionnaire. *Chronic Obstr Pulm Dis* 2017; 4: 124–131.
- 47 Donaldson GC, Law M, Kowlessar B, *et al.* Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 943–950.
- 48 Vestbo J, Edwards LD, Scanlon PD, *et al.* Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011; 365: 1184–1192.
- 49 Casanova C, de Torres JP, Aguirre-Jaime A, *et al.* The progression of chronic obstructive pulmonary disease is heterogeneous. *Am J Respir Crit Care Med* 2011; 184: 1015–1021.
- 50 Lange P, Celli B, Agustí A, *et al.* Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Engl J Med* 2015; 373: 111–122.
- 51 Celli BR, Thomas NE, Anderson JA, *et al.* Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. *Am J Respir Crit Care Med* 2008; 178: 332–338.
- 52 Calverley PMA, Anderson JA, Brook RD, *et al.* SUMMIT (Study to Understand Mortality and Morbidity) Investigators. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. *Am J Respir Crit Care Med* 2018; 197: 47–55.
- 53 Sutherland ER, Allmers H, Ayas NT, *et al.* Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. *Thorax* 2003; 58: 937–941.
- 54 Celli B, Anderson JA, Brook R, *et al.* Long-acting β -agonist/inhaled corticosteroid in patients with chronic obstructive pulmonary disease with cardiovascular disease or risk: a factorial analysis of the SUMMIT clinical trial. *Am J Respir Crit Care Med* 2018; 197: 1641–1644.
- 55 Barnes NC, Sharma R, Lettis S, *et al.* Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. *Eur Respir J* 2016; 47: 1374–1382.
- 56 van den Berge M, Steiling K, Timens W, *et al.* Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. *Thorax* 2014; 69: 14–23.
- 57 Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. *Ann Intern Med* 2003; 138: 969–973.
- 58 Soriano JB, Sin DD, Zhang X, *et al.* A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. *Chest* 2007; 131: 682–689.
- 59 Marriott HM, Daigneault M, Thompson AAR, *et al.* A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. *Thorax* 2012; 67: 985–992.
- 60 Barnes PJ. Corticosteroid effects on cell signalling. *Eur Respir J* 2006; 27: 413–426.
- 61 Suissa S, McGhan R, Niewoehner D, *et al.* Inhaled corticosteroids in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2007; 4: 535–542.
- 62 Tashkin DP, Doherty DE, Kerwin E, *et al.* Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. *Int J Chron Obstruct Pulmon Dis* 2012; 7: 43–55.
- 63 Dekhuijzen PNR, Batsiou M, Bjermer L, *et al.* Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. *Respir Med* 2016; 120: 54–63.
- 64 Ni S, Fu Z, Zhao J, *et al.* Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. *J Thorac Dis* 2014; 6: 971–978.
- 65 Dong Y-H, Chang C-H, Wu F-LL, *et al.* Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. *Chest* 2014; 145: 1286–1297.
- 66 Almirall J, Bolibar I, Serra-Prat M, *et al.* New evidence of risk factors for community-acquired pneumonia: a population-based study. *Eur Respir J* 2008; 31: 1274–1284.
- 67 Torres A, Blasi F, Dartois N, *et al.* Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. *Thorax* 2015; 70: 984–989.
- 68 Wedzicha JA, Banerji D, Chapman KR, *et al.* Indacaterol-glycopyrronium *versus* salmeterol-fluticasone for COPD. *N Engl J Med* 2016; 374: 2222–2234.
- 69 Nannini LJ, Poole P, Milan SJ, *et al.* Combined corticosteroid and long-acting beta 2-agonist in one inhaler *versus* placebo for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2013: CD003794.

- 70 Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta 2-agonist in one inhaler *versus* long-acting beta 2-agonists for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012; CD006829.
- 71 Rodrigo GJ, Neffen H. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD. *Pulm Pharmacol Ther* 2017; 42: 1–6.
- 72 Suissa S, Patenaude V, Lapi F, *et al.* Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax* 2013; 68: 1029–1036.
- 73 Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014; CD010115.
- 74 European Medicines Agency. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD) (EMA/330021/2016). London, UK, 2016.
- 75 Vestbo J, Papi A, Corradi M, *et al.* Single inhaler extrafine triple therapy *versus* long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet* 2017; 389: 1919–1929.
- 76 Singh D, Papi A, Corradi M, *et al.* Single inhaler triple therapy *versus* inhaled corticosteroid plus long-acting β 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. *Lancet* 2016; 388: 963–973.
- 77 Scuri M, Singh D, Fabbri LM, *et al.* Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: post-hoc analysis of the TRIBUTE Study. *Am J Respir Crit Care Med* 2018; 197: A3030.
- 78 Crim C, Calverley PMA, Anderson JA, *et al.* Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. *Respir Med* 2017; 131: 27–34.
- 79 Crim C, Dransfield MT, Bourbeau J, *et al.* Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. *Ann Am Thorac Soc* 2015; 12: 27–34.
- 80 Sin DD, Tashkin D, Zhang X, *et al.* Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. *Lancet* 2009; 374: 712–719.
- 81 Crim C, Calverley PMA, Anderson JA, *et al.* Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. *Eur Respir J* 2009; 34: 641–647.
- 82 Pavord ID, Lettis S, Locantore N, *et al.* Blood eosinophils and inhaled corticosteroid/long-acting β -2 agonist efficacy in COPD. *Thorax* 2016; 71: 118–125.
- 83 Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? *Lancet Respir Med* 2017; 5: 747–759.
- 84 Pavord ID, Lettis S, Anzueto A, *et al.* Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. *Lancet Respir Med* 2016; 4: 731–741.
- 85 Vedel-Krogh S, Nordestgaard BG, Lange P, *et al.* Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. *Eur Respir J* 2018; 51: 1800120.
- 86 Cheng S-L, Su K-C, Wang H-C, *et al.* Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. *Drug Des Devel Ther* 2014; 8: 601–607.
- 87 Ernst P, Gonzalez AV, Brassard P, *et al.* Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. *Am J Respir Crit Care Med* 2007; 176: 162–166.
- 88 Restrepo MI, Mortensen EM, Anzueto A. Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? *Eur Respir J* 2011; 38: 1–3.
- 89 Singanayagam A, Chalmers JD, Akram AR, *et al.* Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. *Eur Respir J* 2011; 38: 36–41.
- 90 Malo de Molina R, Mortensen EM, Restrepo MI, *et al.* Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. *Eur Respir J* 2010; 36: 751–757.
- 91 Chen D, Restrepo MI, Fine MJ, *et al.* Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. *Am J Respir Crit Care Med* 2011; 184: 312–316.
- 92 Lee C-H, Kim K, Hyun MK, *et al.* Use of inhaled corticosteroids and the risk of tuberculosis. *Thorax* 2013; 68: 1105–1113.
- 93 Shu C-C, Wu H-D, Yu M-C, *et al.* Taiwan Anti-Mycobacteria Investigation (TAMI) Group. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. *Medicine (Baltimore)* 2010; 89: 53–61.
- 94 World Health Organization. Global tuberculosis report. Geneva, Switzerland, 2017.
- 95 Brassard P, Suissa S, Kezouh A, *et al.* Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. *Am J Respir Crit Care Med* 2011; 183: 675–678.
- 96 Andr ejak C, Nielsen R, Thomsen V , *et al.* Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. *Thorax* 2013; 68: 256–262.
- 97 Brode SK, Campitelli MA, Kwong JC, *et al.* The risk of mycobacterial infections associated with inhaled corticosteroid use. *Eur Respir J* 2017; 50: 1700037.
- 98 Yang M, Chen H, Zhang Y, *et al.* Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. *Inhal Toxicol* 2017; 29: 219–226.
- 99 Yang IA, Clarke MS, Sim EHA, *et al.* Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane database Syst Rev* 2012; CD002991.
- 100 Calzetta L, Matera MG, Braido F, *et al.* Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. *Pulm Pharmacol Ther* 2017; 45: 148–158.
- 101 Jarad NA, Wedzicha JA, Burge PS, *et al.* An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. *Respir Med* 1999; 93: 161–166.
- 102 O'Brien A, Russo-Magno P, Karki A, *et al.* Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. *Am J Respir Crit Care Med* 2001; 164: 365–371.
- 103 van der Valk P, Monninkhof E, van der Palen J, *et al.* Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. *Am J Respir Crit Care Med* 2002; 166: 1358–1363.

- 104 Wouters E, Postma D, Fokkens B, *et al.* Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. *Thorax* 2005; 60: 480–487.
- 105 Choudhury AB, Dawson CM, Kilvington HE, *et al.* Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. *Respir Res* 2007; 8: 93.
- 106 Nadeem NJ, Taylor SJC, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD—a systematic review and comment on trial methodology. *Respir Res* 2011; 12: 107.
- 107 Magnussen H, Disse B, Rodriguez-Roisin R, *et al.* Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med* 2014; 371: 1285–1294.
- 108 Magnussen H, Tetzlaff K, Bateman ED, *et al.* Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. *Eur Respir J* 2016; 47: 651–654.
- 109 Vogelmeier C, Worth H, Buhl R, *et al.* “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 487–494.
- 110 Kunz LIZ, Postma DS, Klooster K, *et al.* Relapse in FEV1 decline after steroid withdrawal in COPD. *Chest* 2015; 148: 389–396.
- 111 Kunz LIZ, Ten Hacken NHT, Lapperre TS, *et al.* Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. *Eur Respir J* 2017; 49: 1600839.
- 112 Rossi A, van der Molen T, Del Olmo R, *et al.* INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. *Eur Respir J* 2014; 44: 1548–1556.
- 113 Chapman KR, Hurst JR, Frent S-M, *et al.* Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. *Am J Respir Crit Care Med* 2018; 198: 329–339.
- 114 Tashkin DP. To withdraw or not to withdraw inhaled corticosteroids from triple therapy in COPD. *Am J Respir Crit Care Med* 2018; 198: 292–294.
- 115 Kerstjens HA, Brand PL, Hughes MD, *et al.* A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. *N Engl J Med* 1992; 327: 1413–1419.
- 116 Postma DS, Rabe KF. The asthma-COPD overlap syndrome. *N Engl J Med* 2015; 373: 1241–1249.
- 117 Martinez FJ, Vestbo J, Anderson JA, *et al.* Effect of fluticasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction. *Am J Respir Crit Care Med* 2016; 195: 881–888.
- 118 Jones PW, Anderson JA, Calverley PM, *et al.* Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. *Respir Res* 2011; 12: 71.
- 119 Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? *Am J Respir Crit Care Med* 2015; 191: 141–148.
- 120 Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. *Am J Med* 2010; 123: 1001–1006.
- 121 Herth FJF, Bramlage P, Müller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. *Respiration* 2015; 89: 66–75.
- 122 Wang JJ, Rochtchina E, Tan AG, *et al.* Use of inhaled and oral corticosteroids and the long-term risk of cataract. *Ophthalmology* 2009; 116: 652–657.
- 123 Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax* 2011; 66: 699–708.
- 124 Price D, Yawn B, Brusselle G, *et al.* Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. *Prim Care Respir J* 2013; 22: 92–100.
- 125 Wise R, Connett J, Weinmann G, *et al.* Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med* 2000; 343: 1902–1909.
- 126 Siddiqui SH, Guasconi A, Vestbo J, *et al.* Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 523–525.
- 127 Roche N, Chapman KR, Vogelmeier CF, *et al.* Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. *Am J Respir Crit Care Med* 2017; 195: 1189–1197.
- 128 Watz H, Tetzlaff K, Wouters EFM, *et al.* Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med* 2016; 4: 390–398.
- 129 Calverley PMA, Tetzlaff K, Vogelmeier C, *et al.* Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017; 196: 1219–1221.
- 130 Bafadhel M, Peterson S, De Blas MA, *et al.* Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018; 6: 117–126.
- 131 Han MK, Quibrera PM, Carretta EE, *et al.* Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. *Lancet Respir Med* 2017; 5: 619–626.
- 132 Singh D, Kolsum U, Brightling CE, *et al.* Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J* 2014; 44: 1697–1700.
- 133 Hastie AT, Martinez FJ, Curtis JL, *et al.* Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med* 2017; 5: 956–967.
- 134 Kolsum U, Damera G, Pham T-H, *et al.* Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol* 2017; 140: 1181–1184.e7.
- 135 Southworth T, Beech G, Foden P, *et al.* The reproducibility of COPD blood eosinophil counts. *Eur Respir J* 2018; 52: 1800427.
- 136 Oshagbemi OA, Burden AM, Braeken DCW, *et al.* Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. *Am J Respir Crit Care Med* 2017; 195: 1402–1404.

- 137 Yun JH, Lamb A, Chase R, *et al.* Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2018; 141: 2037–2047.
- 138 Vedel-Krogh S, Nielsen SF, Lange P, *et al.* Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. *Am J Respir Crit Care Med* 2016; 193: 965–974.
- 139 Pavord ID, Chanez P, Criner GJ, *et al.* Mepolizumab for eosinophilic chronic obstructive pulmonary disease. *N Engl J Med* 2017; 377: 1613–1629.